PLS3 overexpression is found in two-third of CTCs from breast cancer patients in different stages of EMT and is associated with poor overall survival, especially in patients with luminal type A or triple-negative breast cancer [85]. The gene discussed is PLS3; the disease is triple-negative breast carcinoma.